CHST6

Across TCGA pan-cancer cohorts, CHST6 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated CHST6 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CHST6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHST6 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

OV, LIHC, and LAML are the cancer types where CHST6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
LIHC	OS	Median	All	0.011	0.784	<.001	24	view →
LAML	DFS	Median	All	0.082	0.582	.004	12	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
PRAD	DFS	Median	All	0.589	0.935	.011	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	OS	Median	III,IV	0.257	0.678	.013	6	view →
SKCM	DFS	Median	All	0.549	0.195	.020	4	view →
BLCA	OS	Median	IV	0.153	0.599	.018	3	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

CHST6–OV (OS)

Open the OV breakdown →